Orbus Therapeutics Announces First Patient Enrolled in Phase 1 Clinical Study in Newly Diagnosed Glioblastoma
September 06, 2023 09:00 ET
|
Orbus Therapeutics, Inc.
- The Phase 1 Study will Evaluate Eflornithine in Combination with Temozolomide - PALO ALTO, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Orbus Therapeutics Inc., a private, late-stage...
Orbus Therapeutics Enters Exclusive License Agreement for Intellectual Property Related to Treatment of Rare Pediatric Syndrome with Eflornithine
January 10, 2023 08:00 ET
|
Orbus Therapeutics, Inc.
PALO ALTO, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Orbus Therapeutics Inc., a private, late-stage biopharmaceutical company focused on the development and commercialization of therapies that treat...
Orbus Therapeutics’ Phase 3 Eflornithine STELLAR Study Reaches Full Patient Enrollment
January 19, 2022 09:00 ET
|
Orbus Therapeutics, Inc.
- Phase 3 STELLAR trial evaluating eflornithine in patients with recurrent anaplastic astrocytoma - - Pre-specified interim analysis to test for superiority expected to occur in 2022 - PALO...
Orbus Therapeutics Granted European Patent for Method of Use for Eflornithine
September 28, 2021 10:00 ET
|
Orbus Therapeutics, Inc.
- Patent relates to method for use of eflornithine to treat cancers, including gliomas - PALO ALTO, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Orbus Therapeutics Inc., a private, late-stage...
Orbus Therapeutics Announces Positive Outcome of Pre-Planned Interim Futility Analysis for Phase 3 Eflornithine STELLAR Study
March 02, 2021 10:00 ET
|
Orbus Therapeutics, Inc.
- Independent Data Monitoring Committee recommends continuation of STELLAR study in rare brain cancer - PALO ALTO, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Orbus Therapeutics Inc., a private,...
Orbus Therapeutics Receives U.S. Patent for Eflornithine Formulations
December 23, 2020 10:00 ET
|
Orbus Therapeutics, Inc.
PALO ALTO, Calif., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Orbus Therapeutics Inc., a private, late-stage biopharmaceutical company focused on the development and commercialization of therapies that treat...
Orbus Therapeutics Expands Series A Financing to $71 Million to Support Ongoing STELLAR Phase 3 Study in Rare Brain Cancer
October 22, 2020 17:00 ET
|
Orbus Therapeutics, Inc.
PALO ALTO, Calif., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Orbus Therapeutics Inc., a private, late-stage biopharmaceutical company focused on the development and commercialization of therapies that treat...
Orbus Therapeutics Announces ASCO Study Design Presentation of Pivotal Clinical Trial in Patients with Late-Stage Brain Cancer
June 05, 2017 11:00 ET
|
Orbus Therapeutics, Inc.
PALO ALTO, Calif., June 05, 2017 (GLOBE NEWSWIRE) -- Orbus Therapeutics Inc., a private, clinical-stage biopharmaceutical company focused on the development and commercialization of therapies that...
Orbus Therapeutics Announces Enrollment of First Patient in Phase 3 Trial in Late-Stage Brain Cancer
September 26, 2016 08:02 ET
|
Orbus Therapeutics, Inc.
PALO ALTO, Calif., Sept. 26, 2016 (GLOBE NEWSWIRE) -- Orbus Therapeutics Inc., a private, clinical-stage biopharmaceutical company focused on the development and commercialization of therapies...
Orbus Therapeutics Granted Orphan Drug Designation by European Medicines Agency for Late-Stage Brain Cancer Drug
June 17, 2016 08:30 ET
|
Orbus Therapeutics, Inc.
-- Orphan Drug Designation and Breakthrough Therapy Designation Previously Granted by U.S. Food and Drug Administration -- -- Company Plans to Initiate a Phase 3 Clinical Trial of Eflornithine...